Research Article
Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients
Table 1
Baseline characteristics of study population.
| | Baseline characteristics of study population | L-Sarcoma number (%) | Non-L-sarcoma number (%) | | Trabectedin | Ifosfamide | Trabectedin | Ifosfamide |
| | Age at first dose | Mean (SD) | 55 (12) | 54 (10) | 57 (14) | 45.3 (14) | | Sex | Female | 16 (42.1) | 9 (47.4) | 9 (56.3) | 19 (61.3) | | Male | 22 (57.9) | 10 (52.6) | 7 (43.8) | 12 (38.7) | | ECOG PS | 0 | 18 (47.4) | 10 (52.6) | 9 (56.3) | 8 (25.8) | | 1 + 2 | 20 (52.6) | 9 (47.4) | 7 (43.8) | 23 (74.2) | | Study size | ET-D-010-10 | 38 (100.0) | — | 16 (100.0) | — | | Nielsen et al. | — | 14 (73.7) | — | 17 (54.8) | | Oosterom et al. | — | 5 (26.3) | — | 14 (45.2) | | Drug received | Trabectedin | 38 (100.0) | — | 16 (100.0) | — | | Ifosfamide | — | 19 (100.0) | — | 31 (100.0) | | Disease status | Local disease | 10 (26.3) | 1 (5.3) | 2 (12.5) | 9 (29.0) | | Metastatic disease | 28 (73.7) | 18 (94.7) | 14 (87.5) | 22 (71.0) | | Tumour histology | Leiomyosarcoma | 19 (50.0) | 13 (68.4) | — | — | | Liposarcoma | 19 (50.0) | 6 (31.6) | — | — | | UPS | — | 6 (37.5) | 4 (19.4) | | Synovial sarcoma | — | 5 (31.3) | 7 (22.6) | | Neurogenic sarcoma | — | — | 4 (12.9) | | Hemangiosarcoma | — | — | 3 (9.7) | | Rhabdomyosarcoma | — | — | 3 (9.7) | | Others | — | 5 (31.3) | 8 (25.8) |
|
|
SD: standard deviation; ECOG-PS: ECOG performance score; UPS: undifferentiated pleomorphic sarcoma.
|
